3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Breast Neoplasms
47
Neoplasm Metastasis
9
Neoplasms
8
Prostatic Neoplasms
7
Brain Neoplasms
7
Endometrial Neoplasms
6
Glioblastoma
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Meningioma
3
Carcinoma, Renal Cell
3
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Oligodendroglioma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liposarcoma
2
Hematologic Neoplasms
2
Glioma
2
Breast Neoplasms, Male
2
Breast Diseases
2
Breast Cancer Female
2
Venous Thromboembolism
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
abemaciclib
×
Clear all
NCT03654833
2023-03-14
MiST
University of Leicester
Phase 2
Unknown
186 enrolled